Sleep Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 7, 2025.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 28, 2025.

A recent analysis identified potential safety concerns associated with pitolisant, sodium oxybate, solriamfetol, and modafinil, highlighting distinct adverse event profiles for each narcolepsy treatment.

Normotensive patients with narcolepsy on sodium oxybate had over 50% of a higher risk of new-onset hypertension or antihypertensive medication use compared with nonusers of the treatment.

Neurology News Network. for the week ending February 23, 2025. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 21, 2025.

Marketed as Wakix, the treatment is currently approved in the United States for excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy and for EDS in pediatric patients aged 6 and older.

Total healthcare costs were 14% higher for patients with potentially inappropriate medication use in the Alzheimer-insomnia cohort, with significant contributions from inpatient care, ambulatory care, and pharmacy costs.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 14, 2024.

The president and CEO at Project Sleep highlighted the need for clinicians to facilitate awareness of patient advocacy resources for those living with narcolepsy or idiopathic hypersomnia. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 7, 2024.

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

The president and CEO at Project Sleep talked about the foundational role of social connections and peer support in improving quality of life for individuals with narcolepsy. [WATCH TIME: 5 minutes]

Compared with Alzheimer disease, those with behavioral variant FTD demonstrated increased light sleep (N1%) and reduced deep sleep (N3%), alongside altered sleep dynamics, such as higher transitions between N1 sleep and wake states.

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

Julie Flygare, JD, president and CEO at Project Sleep, discussed the critical role of social connections and peer support in helping individuals with sleep disorders navigate their diagnosis.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Cognitive behavioral therapy for insomnia, a multicomponent psychotherapy, consists of sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.

In a recent survey, key factors associated with perceived support included knowing someone who had the same diagnosis of their sleep disorder, younger age, and marital status.

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.

The neurologist and sleep disorder specialist at Allegheny Health Network discussed the challenges with preventing narcolepsy and the strategies patients can take to improve their overall prognosis. [WATCH TIME: 4 minutes]

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on restless legs syndrome.